相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review
Peter Ghijben et al.
PHARMACOECONOMICS (2018)
Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions
Ting Wang et al.
VALUE IN HEALTH (2018)
Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
Huseyin Naci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Accelerated Approval and Expensive Drugs - A Challenging Combination
Walid F. Gellad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Role of Noncomparative Evidence in Health Technology Assessment Decisions
Elizabeth A. Griffiths et al.
VALUE IN HEALTH (2017)
Conditional approval of medicines by the EMA
Rita Banzi et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Conditional approval of medicines by the EMA
Rita Banzi et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints
Tracy Rupp et al.
JAMA INTERNAL MEDICINE (2017)
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries
S. Kleijnen et al.
ANNALS OF ONCOLOGY (2016)
Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU
Jarno Hoekman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014
Anthony J. Hatswell et al.
BMJ OPEN (2016)
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
Michael Ermisch et al.
Frontiers in Pharmacology (2016)
Adaptive Licensing and Facilitated Regulatory Pathways: A Survey of Stakeholder Perceptions
L. Liberti et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Does Conditional Approval for New Oncology Drugs in Europe Lead to Differences in Health Technology Assessment Decisions?
I. Lipska et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients
H-G Eichler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Approvals of drugs with uncertain benefit-risk profiles in Europe
Rita Banzi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2015)
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review
Bo Wang et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review
Bo Wang et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses
Vinay Prasad et al.
JAMA INTERNAL MEDICINE (2015)
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
Chul Kim et al.
JAMA INTERNAL MEDICINE (2015)
New FDA Breakthrough- Drug Category Implications for Patients
Jonathan J. Darrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration The Class of 2008
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2014)
Equivalences of weighted kappas for multiple raters
Matthijs J. Warrens
STATISTICAL METHODOLOGY (2012)
Interrater reliability: the kappa statistic
Mary L. McHugh
BIOCHEMIA MEDICA (2012)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Progression-Free Survival Is Simply a Measure of a Drug's Effect While Administered and Is Not a Surrogate for Overall Survival
Julia Wilkerson et al.
CANCER JOURNAL (2009)
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures
G Apolone et al.
BRITISH JOURNAL OF CANCER (2005)
分享论文
